amiloride has been researched along with fluoxetine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bagal, SK; Brown, AD; Cox, PJ; Omoto, K; Owen, RM; Pryde, DC; Sidders, B; Skerratt, SE; Stevens, EB; Storer, RI; Swain, NA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Björnsson, E; Davidsdottir, L | 1 |
| Calhau, C; Faria, A; Lemos, C; Martel, F; Meireles, M; Monteiro, R | 1 |
| Barkhof, F; Bastow, R; Braisher, M; Chandran, S; Chataway, J; Connick, P; Cranswick, G; De Angelis, F; Doshi, A; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hawkins, C; John, N; MacManus, D; Ourselin, S; Parker, RA; Pavitt, SH; Plantone, D; Prados Carrasco, F; Ross, M; Sharrack, B; Stallard, N; Stutters, J; Weir, CJ | 2 |
| Barkhof, F; Chataway, J; DeAngelis, F; Doshi, A; Gandini Wheeler-Kingshott, CAM; John, NA; MacManus, D; Marshall, I; Monteverdi, A; Parker, RA; Plantone, D; Prados, F; Schneider, T; Solanky, BS; Stutters, J; Weir, CJ | 1 |
| Chandran, S; Chataway, J; Connick, P; de Angelis, F; Foley, P; Parker, RA; Weir, CJ; Young, C | 1 |
2 review(s) available for amiloride and fluoxetine
| Article | Year |
|---|---|
Ion channels as therapeutic targets: a drug discovery perspective.
Topics: Drug Discovery; Humans; Ion Channels; Models, Molecular; Phylogeny | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for amiloride and fluoxetine
| Article | Year |
|---|---|
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl
Topics: Adult; Amiloride; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2018 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroimaging; Neuroprotective Agents; Proton Magnetic Resonance Spectroscopy; Protons; Riluzole | 2020 |
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuralgia; Riluzole | 2022 |
5 other study(ies) available for amiloride and fluoxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice.
Topics: Adult; Aged; Amiloride; Amoxicillin; Cause of Death; Female; Fluconazole; Fluoxetine; Follow-Up Studies; Halothane; Hepatitis, Autoimmune; Humans; Jaundice; Liver; Male; Middle Aged; Ranitidine; Time Factors | 2009 |
Thiamine is a substrate of organic cation transporters in Caco-2 cells.
Topics: Amiloride; Amprolium; Biological Transport; Caco-2 Cells; Desipramine; Enzyme Inhibitors; Fluoxetine; Humans; Hydrogen-Ion Concentration; Organic Cation Transport Proteins; Oxythiamine; Phosphoric Monoester Hydrolases; Protein Binding; Serotonin; Sodium Chloride; Thiamine | 2012 |